New hope for kids with hemophilia: can SCT800 stop bleeds before they start?
NCT ID NCT07437404
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing a drug called SCT800, a lab-made clotting factor, to prevent bleeding episodes in 36 boys with severe hemophilia A who have never been treated before. Participants receive regular infusions of SCT800, and researchers will monitor how many bleeding events occur and whether the body develops antibodies that could block the treatment. The goal is to see if this approach is safe and effective for long-term prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SCT800 (a recombinant factor VIII replacement therapy)
What this could lead to
If successful, this could provide a safe and effective preventive treatment option for children with severe hemophilia A who have not yet received any factor VIII therapy.
What could go wrong
This is a small, open-label study with no control group, so results may be less reliable. There is a risk of developing inhibitors (antibodies) that block the treatment's effect, a known complication in previously untreated patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing children's hospital
RECRUITINGBeijing, Beijing Municipality, 000000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••